Johnson & Johnson (JNJ)
Johnson & Johnson is a diversified healthcare company spanning innovative pharmaceuticals and medical technology (devices). Following the 2023 spin-off of its consumer-health arm (Kenvue), it is focused on higher-margin prescription drugs and med-tech.
JNJ annual filing snapshot
FY 2025 · filed Feb 11, 2026The latest complete annual figures Tradune found in Johnson & Johnson’s Form 10-K. They describe the reported fiscal year, not a current valuation or forecast.
- Revenue
- $94.2B
- Net income
- $26.8B
- Operating cash flow
- $24.5B
Source: SEC EDGAR Form 10-K ↗. Figures are reported values from the same filing and may reflect a company’s fiscal calendar; they are not investment advice.
JNJ at a glance
- Ticker
- JNJ (NYSE)
- Sector
- Health Care
- Industry
- Pharmaceuticals & Medical Devices
- Headquarters
- New Brunswick, New Jersey, USA
- Founded
- 1886
- CEO
- Joaquin Duato
- Dividend
- Yes
- Volatility
- Lower than the market
Does Johnson & Johnson pay a dividend?
A Dividend King with more than six decades of annual increases. It is one of the most reliable dividend payers in the market, favored for stability rather than a high yield.
How risky is JNJ?
Historically, Johnson & Johnson's share price has been lower than the market (a rough beta band of ~0.5–0.7 — a long-run tendency, not a live figure). The structural risks worth understanding:
- Patent cliffs — key drugs eventually lose exclusivity to generics.
- Ongoing product-liability litigation (a recurring overhang).
- Regulatory and drug-pricing pressure in the US and abroad.
- R&D risk: expensive trials that can fail late.
What gives JNJ its edge
A deep drug pipeline, entrenched medical-device franchises, and the scale to fund years of R&D — plus a diversification across therapies that smooths any single setback.
What actually moves the stock
- Pipeline readouts and new drug approvals.
- Litigation developments and settlement sizing.
- Med-tech growth and the impact of drug-pricing policy.
JNJ earnings analysis
What Johnson & Johnson actually reported, where the reported numbers are strong or thin, and what to check next — every figure sourced to the results release.
Tracking JNJ in a portfolio
The profile above is the slow-moving, structural picture. The parts that change week to week — insider buying and selling, analyst revisions, risk contribution to your specific portfolio — are where a tool earns its keep. For background on reading those signals, see our guides on insider cluster buying and portfolio risk.
See recent JNJ insider filings →Frequently asked about JNJ
Does Johnson & Johnson (JNJ) pay a dividend?
Yes, and it is a "Dividend King" with over 60 consecutive years of increases — one of the most dependable dividend records in the market.
What changed after the Kenvue spin-off?
J&J separated its consumer-health business (brands like Band-Aid and Tylenol) into Kenvue in 2023, leaving J&J focused on higher-margin pharmaceuticals and medical devices.
Who is the CEO of Johnson & Johnson?
Joaquin Duato, who has served as CEO since 2022 and is also Chairman.
Compare JNJ
Track JNJ — and everything else — in one place
Tradune tracks insider filings, risk contribution and alerts across your whole portfolio.
Start freeFree for everyone right now · no card · nothing to buy
Johnson & Johnson (JNJ) information on this page is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Company profiles reflect long-term, structural facts; figures such as beta are approximate historical tendencies, not live data. Always do your own research.